Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Jun 25, 2024 6:14pm
143 Views
Post# 36105981

RE:RE:RE:Time's Up...

RE:RE:RE:Time's Up...Yup, I downsized my position. Since Matt hadn't mentioned Accelerated Approval wrt to mBC, and since they were only planning to release full results later in the year, I reasoned that a value inflection point would still not come until Q3 at the earliest, so this was just dead money.

But each to their own... I might miss the big rise, so I'll only get a quarter of what I once might have... If I had deep confidence in the company's ability to find a partner I wouldn't have sold.

And as if by Magic, Matt is suddenly taken ill... there's just too much fluff and fluster with ONCY, and never anything truly substantive to hold a bigger position.

GLTA...  
<< Previous
Bullboard Posts
Next >>